- Trial Phase
- Phase 2 (first-line NSCLC); registrational trial (melanoma)
- Time to Market
- Not approved. EIK1001 is Phase 2 in first-line NSCLC with a registrational trial running in melanoma; if the registrational trial's interim/final analyses succeed, a regulatory filing is likely still 2027-2028 at the earliest — years away and high-risk.
- Why 6/10
- Next hard catalyst: interim analyses for EIK1001's melanoma registrational trial and Phase 2 NSCLC data readouts, both guided for 2H 2026 in the Aug 13, 2026 corporate presentation (with ESMO 2026 abstract presentations near-term) — a pivotal-adjacent readout within ~6 months on the lead asset at a company that also has other pipeline programs, hence 6.
Watch for the 2H 2026 melanoma registrational interim analysis and Phase 2 NSCLC readouts (and the ESMO 2026 data presentations, typically September). The stock carries heavy short interest (~9% of estimated shares outstanding, ~20 days-to-cover as of the 7/31/26 settlement) and a wide analyst split (mean target $24.6 vs. Wedbush's Underperform/$7.00), so these readouts could trigger outsized moves in either direction. Verify the exact ESMO presentation date, which was not disclosed in the sources reviewed.
Price Chart
Executive Summary
EIK1001 is Eikon Therapeutics' (Nasdaq: EIKN) lead candidate, a TLR7/8 agonist in Phase 2 for first-line non-small cell lung cancer, with a registrational trial in melanoma. At ASCO 2026 the company reported a 63.1% overall response rate and 90.8% disease control rate across 65 evaluable NSCLC patients, and it has guided to melanoma registrational-trial interim analyses plus Phase 2 NSCLC readouts in 2H 2026. The stock trades at $12.01 (8/19/26) with a bullish analyst consensus (mean target $24.6) but persistent bearish signals: Wedbush's Underperform rating, rising short interest, high short-volume flow, and a history of ~12% declines on prior neutral clinical filings.
How It Works
EIK1001 is a small-molecule agonist of Toll-like receptors 7 and 8 (TLR7/8) — an immune "alarm bell" found on certain white blood cells. By activating these receptors, the drug is designed to wake up the body's own immune system to recognize and attack tumor cells, a different immune pathway than checkpoint inhibitors like PD-1 blockers. It is given as an outpatient treatment.
Trial Status
Updated Phase 2 data presented at ASCO 2026 (May 30, 2026): 63.1% ORR and 90.8% DCR across 65 evaluable first-line NSCLC patients, median duration of response >11 months in the non-squamous cohort, with a manageable safety profile supporting outpatient administration. Company guidance (Aug 13, 2026 8-K/corporate presentation) calls for melanoma registrational-trial interim analyses and Phase 2 NSCLC readouts in 2H 2026; seven abstracts across EIK1001/EIK1003/EIK1004/EIK1005 were accepted for the 2026 ESMO Congress.
The Two-Sided Case
Upcoming Catalysts
- Melanoma registrational-trial interim analyses (guided 2H 2026)
- Phase 2 NSCLC data readouts (guided 2H 2026)
- 2026 ESMO Congress data presentations (7 abstracts accepted; date not disclosed in sources reviewed)
- Ongoing FINRA semi-monthly short-interest settlements (~9% of est. shares outstanding as of 7/31/26)
- Q3 2026 earnings / clinical update call
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Eikon Therapeutics, Inc. Press Release EIKN ·Originating report